The role of TLR4, TNF-α and IL-1β in type 2 diabetes mellitus development within a North Indian Population. by Nat Doody (3089046) et al.
The role of TLR4, TNF-α and IL-1β in type 2 diabetes mellitus development within a North 
Indian Population. 
 
NATALIE E. DOODY, MONIKA DOWEJKO, ELIZABETH C. AKAM, NICK J. COX, 
JASVINDER S. BHATTI, PUNEETPAL SINGH, SARABJIT S. MASTANA 
 
 
 
 
Author Addresses:  
NE Doody, M Dowejko, EC Akam, NJ Cox and SS Mastana 
School of Sport, Exercise and Health Sciences, 
Loughborough University,  
Loughborough LE11 3TU, UK 
 
Jasvinder S Bhatti 
Department of Biotechnology and Bioinformatics, Sri Guru Gobind Singh College, Sector 26, 
Chandigarh – India 
Puneetpal Singh,  
Department of Human Genetics, Punjabi University, Patiala, Punjab, India. 
 
Address for correspondence  
Natalie E Doody or Sarabjit Mastana 
School of Sport, Exercise and Health Sciences, 
Loughborough University,  
Loughborough LE11 3TU, UK 
N.E.Doody@lboro.ac.uk  or S.S.Mastana@lboro.ac.uk 
 
Short running head: Inflammatory gene polymorphisms and type 2 diabetes mellitus. 
 
Key words: Type 2 diabetes mellitus; TLR4 896; TNF-α -308; IL-1β -511;               
Inflammatory gene polymorphisms; North Indian population 
  
SUMMARY 
This study investigated the role of IL-1β-511 (rs16944), TLR4-896 (rs4986790) and TNF-α-
308 (rs1800629) polymorphisms in type 2 diabetes mellitus (T2DM) among an endogamous 
Northern Indian population. 414 participants (204 T2DM patients and 210 non-diabetic 
controls) were genotyped for IL-1β-511, TLR4-896 and TNF-α-308 loci. The C allele of IL-
1β-511 was shown to increase T2DM susceptibility by 75% (OR: 1.75 [CI 1.32-2.33]). 
Having two parents affected by T2DM increased susceptibility by 5.7 times (OR: 5.693 [CI 
1.431-22.648]). In this study, we have demonstrated a conclusive association with IL-1β-511 
locus and IL1B-511-TLR4-896 diplotype (CC-AA) and T2DM, which warrants further 
comprehensive analyses in larger cohorts. 
INTRODUCTION  
South Asians’ are approximately five times more likely to develop T2DM, and its 
comorbidities, at an earlier age than white Europeans (Ramachandran et al., 2013). There are 
estimated 65 million cases of T2DM in India, which will double within the next two decades 
(Ramachandran et al., 2013). 
T2DM is a complex metabolic condition characterised by an individual’s inability to regulate 
blood sugar levels resulting in hyperglycaemia. T2DM is caused due to either a lack of 
insulin production from the pancreas or the body’s tissues developing a resistance to insulin; 
and is normally preceded by low-grade inflammation and the release of inflammatory 
cytokines (Cruz et al., 2013). Inflammation and its pathways have been targeted in recent 
research on pathology and treatment of the disease among other gene targets (Brunetti et al., 
2014; Goldfine and Shoelson, 2017). 
 
Toll like receptor 4 (TLR4) protein is responsible for the mediation of immune responses and 
inflammation activation (Takeda et al., 2003). Interleukin-1β (IL-1β), a pro-inflammatory 
cytokine, protects against infection and stimulates neutrophils and macrophages to initiate 
phagocytosis (Netea et al., 2010). Tumor necrosis factor alpha (TNF-α) is another pro-
inflammatory cytokine involved in the recovery from tissue damage, infection, and facilitates 
the movement of immune cells to defective tissues (Barbara et al., 1996).  
 
Preclinical studies indicate TNF-α induces insulin resistance (Hotamisligil et al., 1993)  and 
there is some evidence that  TNF-α inhibitors reduce glycaemia, fasting glucose levels and 
diabetes incidence (Stanley et al., 2011; Goldfine and Shoelson, 2017). Preclinical and 
clinical studies also report IL-1β involvement in T2DM pathogenesis (Koenen et al., 2011; 
Sloan-Lancaster et al., 2013).  The antagonist IL-1Ra inhibits IL-1β signalling and alleviated 
systemic inflammation and glycaemia in T2DM patients (Larsen et al., 2007). The expression 
of TLR4, IL-1β and TNF-α is also modulated by glucagon-like peptide-1 receptor agonist 
(Exenatide) among diabetics (Chaudhuri et al., 2011). This provides a rationale for the 
candidate genes featuring in this study to be investigated as they have the potential to form 
future drug targets for T2DM therapy. 
 
IL-1β-511 (rs16944:T>C), TLR4-896 (rs4986790:A>G) and TNF-α-308 (rs1800629:G>A) 
polymorphisms are associated with T2DM in European, Mexican, Moroccan and Indian 
populations (Achyut et al., 2007; Assman et al., 2014; Sefri et al., 2014; Saxena et al., 2015 
and Tripathi et al., 2015), although studies on Indian populations are limited. Genetic 
analyses of inflammatory genes contribute to the development of prognostic markers which 
could be used to distinguish individuals at risk. Therefore, it will be beneficial to conduct 
comprehensive studies on Indian subpopulations to disentangle the genetic burden of T2DM. 
This study aims to investigate the association of IL-1β-511, TLR4-896 and TNF-α-308 
polymorphisms with T2DM in an endogamous Northern Indian population. 
 
MATERIALS AND METHODS 
Study Subjects 
This study consisted of 204 T2DM patients (104M;100F) and 210 non-diabetic unrelated 
controls (87M;123F). Participants belong to the endogamous group of Lobana Sikhs-an 
agriculturist population from Punjab, North India and were sampled in early 1990s as part of 
ongoing genetic and disease studies (Mastana et al., 2013).  Samples were collected from 
unrelated patients and controls after obtaining written informed consent.  T2DM status was 
diagnosed by either a medical record or tests showing fasting glucose levels [7.0 mmol/l or 
[126 mg/dl after a minimum 12-h fast or 2-h post glucose level (oral glucose tolerance test or 
2-h OGTT) [11.1 mmol/l or 200 mg/dl] on more than one occasion. Control participants were 
free of diabetes symptoms and were matched to the patients for age, gender and geographical 
location.  The current study was approved by the ethics committees of local medical hospitals 
and colleges and Loughborough University. Further details of clinical/diagnostic and 
demographic features of these samples are given in a previous study (Mastana et al., 2013). 
Genotyping 
IL-1β-511 (rs16944) polymorphism was amplified and analysed using PCR- restriction 
fragment length polymorphism method (PCR-RFLP) (Mirowska-Guzel et al., 2011). TLR4-
896 (rs4986790) and TNF-α-308 (rs1800629) polymorphisms were genotyped using 
TaqMan® assays (Assay ID C__11722238_20 and C___7514879_10, respectively). 10% of 
samples were repeated to check genotyping reliability.  
 Statistical Analysis 
Continuous variables were compared using means and standard deviations (unpaired t-tests). 
Chi-square analysis (χ2) was performed to assess the difference in genotypic and allele 
frequencies and to test for Hardy Weinberg equilibrium (HWE). Odds ratios (ORs) and 95% 
confidence intervals (CI) were calculated to assess the risk of T2DM with differing genotypes 
and alleles. Synergistic analysis was carried out for different genotype combinations 
(diplotypes and triplotypes). Binary logistic regression was performed to determine if any 
genetic, demographic or biochemical covariates were independent predictors of T2DM. P-
values of <0.05 were considered statistically significant. Bonferroni corrections were applied 
to control for multiple comparisons. Statistical tests were conducted using the Statistical 
Package of Social Sciences (SPSS) for Windows, version 23.0 (SPSS, Inc., Chicago, IL). 
RESULTS  
Demographics 
The anthropometrical, biochemical, and clinical characteristics of the patient and control 
populations are summarised in Table 1. Patients, on average, were taller and heavier than 
controls, with larger waist and hip measurements and a larger waist hip ratio (WHR). Systolic 
blood pressure (SBP) was shown to be significantly higher in patients. High-density 
lipoprotein (HDL) levels were lower in patients than the controls (P<0.005).  
Genotype and allele distribution 
The distribution of different genotypes and alleles within patients and controls are presented 
in Table 2, along with synergistic effects at diplotype and triplotype combinations. Both 
patients and controls were within HWE for IL-1β-511 and TLR4-896. At TNF-α-308 locus, 
only the patients were in HWE (χ2= 3.539), and controls violated the HWE even after 
Bonferroni correction (χ2  = 8.328). 
The frequency of the IL-1β-511 CC genotype was higher in patients (19.8%) than in controls 
(10.4%). The C allele of IL-1β-511 increases the risk of T2DM by about 75% (OR: 1.75 (CI 
1.32-2.33)) while T allele exerted a protective effect (OR: 0.57 (CI 0.43-0.76)).   
TLR4-896 genotype distribution was similar between patients and controls.  Neither A or G 
allele of TLR4-896 had a statistically significant association with the disease.  
At TNF-α -308 locus, 89.9% of patients and 92.6% of controls possessed the most common 
GG genotype, whereas the frequency of the rare AA genotype was similar in both groups 
(1%). TNF-α-308 also showed no statistically significant allelic or genotypic association with 
T2DM, though heterozygote GA genotype increased the risk by 47% (OR: 1.47 [CI 0.70-
3.09]). 
Synergistic Effect 
The synergistic effect of genotypic combinations is presented in Table 2. Four diplotype and 
3 triplotype combinations were statistically significant before the Bonferroni correction. After 
the correction, only IL-1β-511-TLR4-896 diplotype combination CC-AA remained 
significantly associated with T2DM, although mean glucose levels did not present a 
statistically significant difference when compared to the reference genotype (TT-AA).  
Binary logistic regression   
Binary logistic regression analysis was carried out at two levels; in genotype only analysis 
(Table 3), ORs and associated significance values were broadly similar to the analyses given 
in Table 2. Table 4 gives the results of a logistic regression analysis including selected 
demographic and clinical variables, where the IL-1β (CC genotype) remains a significantly 
susceptible genotype. TLR4 genotypes AG and GG change the direction of the effect and 
become susceptible. The regression analysis showed that having both parents affected by 
T2DM increases individual’s risk by 5.7 times. BMI, SBP, DBP and HDL levels are all 
independent predictors of T2DM in this population.   
DISCUSSION 
This is the first study on a well characterised endogamous sample, analysing inflammatory 
genes for their association with T2DM. In this study, C allele of IL-1β-511 increased the 
likelihood of T2DM (OR: 1.75 [CI = 1.32-2.33]) while T allele exerted a protective effect 
(OR: 0.57 [CI = 0.43-0.76]), and the TC and CC genotypes increased T2DM risk when 
compared to TT (OR: 1.89 [CI = 1.23-2.92] and OR: 3.10 [CI = 1.66-5.78], respectively).  
Mojtaba et al. (2011) reported a significant association between increased IL-1β levels and 
decreased insulin concentration; decreased β cell function and increased fasting glucose. 
Further research should be conducted to decipher which allele/genotype of IL-1β induces 
these effects. 
The present results contradict some previous studies where the T allele was associated with 
T2DM. (Achyut et al., 2007; Saxena et al., 2015 and Tripathi et al., 2015). The previous 
studies are difficult to interpret due to ambiguity in genotyping methods. Two studies report 
the C allele to be 304bp and T allele 189 and 116bp (Saxena et al., 2015 and Tripathi et al., 
2015). This study coded the alleles in the same manner as Mirowska-Guzel et al. (2011) and 
Achyut et al. (2007) (T:304bp; C:190+114bp). Genotyping calls in this study were also 
confirmed using a TaqMan® assay which provides confidence in these results.  The 
aforementioned publications analysed heterogeneous Indian populations recruited from 
outpatient clinics and hospitals, however, the present sample is from a field based study on a 
homogenous and endogamous Sikh population (Mastana et al 2013). 
Although statistically insignificant trends were observed for the A allele of the TNF-α-308 
locus and G allele of TLR4-896 locus, further studies are warranted with larger samples to 
confirm/evaluate these associations (Sefri et al., 2014; Assman et al., 2014).    
The inconsistent results of IL-1β-511, TLR4-896 and TNF-α-308 association with T2DM 
across a range of populations suggests that ethnicity may play a role in how these genes 
interact with the disease. Populations from different geographical regions are exposed to 
different environmental risk factors, thus different gene-environment interactions are formed. 
This can alter how the genes influence T2DM in different populations, therefore producing 
inconclusive results.  
IL-1β-511 seems to be the main contributor to susceptibility in the diplotype IL-1β-511-
TLR4-896 (Table 2), due to the increased risk associated with the C allele.  Synergistic effect 
is not a purely additive model and the increased susceptibility is attributable to the 
combination of independent risk alleles at both loci. IL-1β and TLR4 activity in macrophages 
can be suppressed by Dipeptidyl peptidase-4 inhibitors, thus potentially having an 
antihyperglycaemic effect (Dai et al., 2014). It is of great importance to conduct further 
preclinical/clinical studies on these candidate genes in order to develop drug therapies for 
T2DM (Chaudhuri et al., 2011; Goldfine and Shoelson, 2017). 
The regression analysis confirmed significant independent association between T2DM and 
the IL-1β-511 CC genotype, family history of T2DM, BMI, SBP, DBP, and HDL levels. In 
this study, positive family history presents the largest risk to offspring when both parents 
have T2DM (OR = 5.693, CI 1.431-22.648).   Maternal diabetes alone increased T2DM risk 
by 5.086 times, suggesting that maternal diabetes exerts a higher risk to offspring than 
paternal diabetes.   
In this study, we have demonstrated a conclusive association with IL-1β and T2DM. IL-1β 
and TLR4 polymorphisms conclusively contribute to T2DM in a synergistic fashion. 
Research has also shown that above polymorphisms have been targeted in drug development 
to reduce inflammation in diabetics; further population focused interventions are required to 
improve gene based treatments. Maternal diabetes is a strong independent determinant of 
T2DM in this population. Further comprehensive studies on different geographical 
populations are warranted with larger samples to clarify the role of inflammatory gene 
polymorphisms in T2DM in Indian population.  
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Table 1. Anthropometrical, biochemical and clinical characteristics of participants.  
   
N 
 
Mean 
 
Std. 
Deviation 
 
Std. Error 
Mean 
 
T test 
P value 
 
Age (years) Patients 204 61.374 10.538 0.738 0.446 
Controls 
 
210 60.465 13.480 0.930  
Height (cm) Patients 204 160.758 9.103 0.637 0.0191* 
Controls 
 
210 158.660 9.037 0.624  
Weight (kg) Patients 204 70.967 12.763 0.894 0.0089* 
Controls 
 
210 67.597 13.312 0.919  
BMI Patients 204 27.488 4.623 0.324 0.173 
Controls 
 
210 26.852 4.850 0.335  
Waist (in.) Patients 204 37.049 4.168 0.292 0.0001* 
Controls 
 
210 35.195 4.482 0.309  
Hip (in.) Patients 204 38.414 3.771 0.264 0.0121* 
Controls 
 
210 37.513 3.497 0.241  
WHR Patients 204 0.965 0.065 0.005 0.0004* 
Controls 
 
210 0.939 0.082 0.006  
Body fat % Patients 204 35.889 10.475 0.733 0.481 
Controls 
 
210 35.210 9.083 0.627  
SBP (mmHg) Patients 204 148.800 21.738 1.522 0.0015* 
Controls 
 
210 141.100 26.869 1.854  
DBP (mmHg) Patients 204 84.270 10.959 0.767 0.191 
Controls 
 
210 82.730 12.846 0.886  
Cholesterol (mg/dl) Patients 194 187.650 48.340 3.471 0.829 
Controls 
 
130 186.470 47.680 4.182  
Triglycerides (mg/dl) Patients 194 184.884 114.195 8.199 0.435 
Controls 
 
130 175.614 88.602 7.771  
HDL (mg/dl) Patients 193 39.218 12.545 0.903 0.0017* 
Controls 
 
130 43.585 11.570 1.015  
LDL (mg/dl) Patients 191 109.444 44.915 3.250 0.529 
Controls 
 
130 106.432 37.294 3.271  
VLDL (mg/dl) Patients 191 39.612 29.732 2.151 0.111 
Controls 130 34.966 17.625 1.546  
*Significance at P<0.05 
BMI – body mass index, WHR – waist hip ratio, SBP – systolic blood pressure, DBP – diastolic blood pressure, 
HDL – high-density lipoprotein, LDL – low-density lipoprotein, VLDL – very low-density lipoprotein.  
 
Table 2. Genotype, allele, diplotype and triplotype frequencies 
Locus Genotype Patients (%) Controls (%) Odds Ratio (95% CI) P value 
      
IL1- β -511 TT 56 (27.7) 91 (44.8) 1.00 (Ref)  
TC 106 (52.5) 91 (44.8) 1.89 (1.23-2.92) 0.005* 
CC 40 (19.8) 21 (10.4) 3.10 (1.66-5.78) 0.001* 
HWE X2 value  0.636 0.062 
 
  
Allele T 218 (54.0%) 273 (67.2%) 0.57 (0.43-0.76) <0.005* 
 C 186 (46.0%) 133 (32.8%) 1.75 (1.32-2.33) <0.005* 
TLR4 896 
 
 
AA 153 (76.9) 147 (72.4) 1.00 (Ref)  
AG 40 (20.1) 48 (23.6) 0.80 (0.50-1.29) 0.427 
GG 6 (3.0) 8 (3.9) 0.72 (0.24-2.13) 0.747 
 
HWE X2 value  2.639 2.441 
 
  
Allele A 346 (87.0) 342 (84.2) 1.25 (0.84-1.85) 0.323 
 G 52 (13.0) 64 (15.8) 0.80 (0.54-1.19) 0.323 
TNF-α -308 GG 178 (89.9) 189 (92.6) 1.00 (Ref)  
GA 18 (9.1) 13 (6.4) 1.47 (0.70-3.09) 0.403 
AA 2 (1.0) 2 (1.0) 1.06 (0.15-7.62) 0.658 
 
HWE X2 value  3.539 8.328**  
 
 
Allele G 374 (94.4) 391 (95.8) 0.74 (0.39-1.14) 0.452 
 A 22 (5.6) 17 (4.2) 1.35 (0.71-2.59) 0.452 
Two Loci Genotypes      
IL1- β -511 
and 
TLR4 896 
TT-AA 33 57 1.00 (Ref)  
TT-GG 3 5 1.04 (0.23-4.62) 0.737 
TT-AG 16 25 1.11 (0.52-2.36) 0.949 
TC-AA 87 69 2.18 (1.28-3.71) 0.006 
TC-AG 16 16 1.73 (0.76-3.90) 0.266 
TC-GG 2 3 1.15 (0.18-7.25) 0.620 
CC-AA 32 15 3.68 (1.74-7.79) 0.001*** 
CC-AG 7 6 
 
2.02 (0.62-16.50) 
 
0.377 
TNF-α -308 
and 
IL1- β -511 
 
GG-TT 50 82 1.00 (Ref)  
GG-TC 93 83 1.84 (1.16-2.91) 0.013 
GG-CC 33 19 2.85 (1.46-5.54) 0.003 
GA-TT 4 4 1.64 (0.39-6.85) 0.757 
GA-TC 7 5 2.30 (0.69-7.63) 0.281 
GA-CC 7 2 5.74 (1.15-28.73) 
 
0.045 
TLR4 896 
and 
TNF-α -308 
AA-GG 132 137    1.00 (Ref)  
GG-GG 4 8 0.52 (0.15-1.76) 0.440 
AA-GA 14 9 1.61 (0.68-3.86) 0.385 
AA-AA 1 1 1.04 (0.06-16.77) 0.494 
AG-GG 37 42 0.91 (0.55-1.51) 0.825 
AG-GA 2 4 0.52 (0.09-2.88) 0.726 
AG-AA 1 1 1.04 (0.06-16.77) 0.494 
     
Three Loci Genotypes  TT-AA-GG 29 53 1.00 (Ref)   
IL1- β -511, 
TLR4 896 
And 
TNF-α -308 
TT-GG-GG 2 5 0.73 (0.13-4.01) 0.959 
TT-AG-GG 15 22 1.25(0.56-2.27) 0.737 
TT-AA-GA 2 3 1.22 (0.19-7.71) 0.786 
TT-AG-GA 1 1 1.83 (0.11-30.31) 0.749 
TC-AA-GG 77 66 2.13 (1.22-3.73) 0.011 
TC-AG-GG 14 14 1.83 (0.77-4.35) 0.252 
TC-GG-GG 1 3 0.61 (0.06-6.13) 0.910 
TC-AA-GA 5 3 3.05 (0.68-13.67) 0.259 
TC-AG-GA 1 2 0.91 (0.08-10.51) 0.587 
CC-AA-GG 25 14 3.26 (1.47-7.23) 0.005 
CC-AG-GG 7 5 2.56 (0.75-8.79) 0.226 
CC-AA-GA 7 1 12.79 (1.50-109.13) 0.013 
     
* - Statistically significant at P<0.05, ** - Population not within Hardy Weinberg Equilibrium, ***- Statistically 
significant at P≤0.001 (after Bonferroni correction) 
 
Table 3. Genotype only binary logistic regression 
Significant predictors of T2DM are indicated in bold. 
Significant predictors of T2DM are indicated in bold. 
 
Predictor Variable Regression 
Coefficient 
Sig. Exp(B) 95% C.I for Exp(B) 
Lower Upper 
IL1β -511  0.001    
(TC) 0.646 0.006 1.907 1.209 3.009 
(CC) 1.064 0.001 2.897 1.546 5.431 
TLR4 896  0.957    
(AG) -0.064 0.803 0.938 0.568 1.548 
(GG) -0.104 0.854 0.901 0.297 2.735 
TNF-α -308  0.753    
(GA) 0.280 0.473 1.323 0.616 2.842 
(AA) 0.247 0.809 1.281 0.173 9.502 
Table 4. Binary logistic regression of genotypes, demographic and clinical variables 
Significant predictors of T2DM are indicated in bold. 
Predictor Variable Regression 
Coefficient 
Sig. Exp(B) 95% C.I for Exp(B) 
Lower Upper 
IL1β -511  0.107    
(TC) 0.256 0.415 1.292 0.698 2.393 
(CC) 0.916 0.035 2.498 1.066 5.855 
TLR4 896  0.171    
(AG) 0.622 0.085 1.864 0.917 3.787 
(GG) 0.868 0.368 2.381 0.360 15.745 
TNF-α -308  0.750    
(GA) 0.061 0.906 1.063 0.385 2.938 
(AA) -1.000 0.455 0.368 0.027 5.075 
Gender (Male) -4.037 0.134 0.018 0.000 3.488 
AGE (Years) 0.014 0.622 1.014 0.960 1.071 
PARENT AFFECTED  0.000    
(Father affected) 0.819 0.039 2.268 1.042 4.939 
(Mother affected) 1.629 0.000 5.086 2.231 11.593 
(Both parents affected) 1.739 0.014 5.693 1.431 22.648 
BMI -0.157 0.011 0.855 0.758 0.964 
WAIST 0.375 0.062 1.454 0.981 2.156 
HIP 0.139 0.103 1.149 0.972 1.358 
BODYFAT (%) -0.204 0.165 0.816 0.612 1.087 
SBP 0.035 0.000 1.036 1.019 1.053 
DBP -0.044 0.007 0.957 0.927 0.988 
CHOLESTEROL -0.002 0.774 0.998 0.988 1.009 
TRIGYCERIDES -0.047 0.095 0.954 0.903 1.008 
HDL -0.039 0.002 0.961 0.938 0.986 
LDL 0.003 0.610 1.003 0.991 1.015 
VLDL 0.241 0.089 1.272 0.964 1.679 
Constant -6.839  0 .020 0.001   
